Recombinant Proteins Market to reach USD 5.0 billion by 2032 with a growing CAGR of 7.6%.

Driven primarily by the increasing prevalence of chronic diseases such as granulomatous disease, hemophilia, sclerosis, and cancer, the global recombinant proteins market is growing very rapidly. Advancements in biologics and biosimilars, and better products being designed and manufactured for recombinant proteins, will remain catalysts for growth. Research and development has accelerated, especially during the COVID-19 pandemic, in developing recombinant protein-based vaccines and therapeutics. This boom in innovation ended up changing the landscape of biopharmaceuticals as companies rushed to create safe and effective treatments. The increased demand for large-scale production of vaccines and therapeutic drugs during the pandemic also increased biologics research, which supports the interests of recombinant protein industries positively.